Su-Jin Shin1, Jin Roh1, Hee Jeong Cha2, Yoo Duk Choi3, Jin-Man Kim4, Soo Kee Min5, Ji Eun Kim6, Dae-Woon Eom7, Hojung Lee8, Hyun-Jung Kim9, Dok Hyun Yoon10, Cheolwon Suh10, Jooryung Huh1. 1. Departments of Pathology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. 2. Department of Pathology, Ulsan University Hospital, University of Ulsan College of Medicine, Ulsan, Korea. 3. Department of Pathology, Chonnam National University Medical School, Gwangju, Korea. 4. Department of Pathology, Chungnam National University School of Medicine, Daejeon, Korea. 5. Department of Pathology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea. 6. Department of Pathology, Seoul National University Boramae Hospital, Seoul, Korea. 7. Departments of Pathology, University of Ulsan College of Medicine, Gangneung Asan Hospital, Gangneung, Korea. 8. Department of Pathology, Eulji Medical Center, Eulji University School of Medicine, Seoul, Korea. 9. Department of Pathology, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea. 10. Departments of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Abstract
OBJECTIVES: Mantle cell lymphoma (MCL) has a heterogeneous clinical course. Although most cases show a poor prognosis, a minority has an indolent course. It is difficult to identify indolent MCL cases prospectively. T-cell leukemia/lymphoma protein 1 (TCL1) is expressed by several B-cell lymphomas, including MCL. This study examined the expression of TCL1 and its prognostic relevance for MCL. METHODS: Clinical data for 162 patients with MCL were collected. Of these, 144 cases with available tissues for tissue microarray construction and immunostaining were included in the analysis. TCL1 staining was quantified using the Nuclear Quant application with Pannoramic™ Viewer v. 1.14. High TCL1 expression was defined as moderate to strong nuclear and/or cytoplasmic staining in 40% or more of the cells. RESULTS: High TCL1 expression was observed in 39 of 144 samples (27.1%). Patients with low TCL1 expression were more likely to present with blastoid/pleomorphic morphology (P = 0.010). Low TCL1 expression was associated with significantly shorter overall survival (OS, P = 0.006). Multivariate analysis identified low TCL1 expression (P = 0.003), high-risk MIPI (P = 0.027), and anemia (P = 0.018) as adverse prognostic factors. CONCLUSIONS: Our study suggests that TCL1 expression profile may have a role in the prediction of overall outcome in patient with MCL and call for prospective studies.
OBJECTIVES:Mantle cell lymphoma (MCL) has a heterogeneous clinical course. Although most cases show a poor prognosis, a minority has an indolent course. It is difficult to identify indolent MCL cases prospectively. T-cell leukemia/lymphoma protein 1 (TCL1) is expressed by several B-cell lymphomas, including MCL. This study examined the expression of TCL1 and its prognostic relevance for MCL. METHODS: Clinical data for 162 patients with MCL were collected. Of these, 144 cases with available tissues for tissue microarray construction and immunostaining were included in the analysis. TCL1 staining was quantified using the Nuclear Quant application with Pannoramic™ Viewer v. 1.14. High TCL1 expression was defined as moderate to strong nuclear and/or cytoplasmic staining in 40% or more of the cells. RESULTS: High TCL1 expression was observed in 39 of 144 samples (27.1%). Patients with low TCL1 expression were more likely to present with blastoid/pleomorphic morphology (P = 0.010). Low TCL1 expression was associated with significantly shorter overall survival (OS, P = 0.006). Multivariate analysis identified low TCL1 expression (P = 0.003), high-risk MIPI (P = 0.027), and anemia (P = 0.018) as adverse prognostic factors. CONCLUSIONS: Our study suggests that TCL1 expression profile may have a role in the prediction of overall outcome in patient with MCL and call for prospective studies.
Authors: L Deng; Z Y Xu-Monette; S Loghavi; G C Manyam; Y Xia; C Visco; J Huh; L Zhang; Q Zhai; Y Wang; L Qiu; K Dybkær; A Chiu; A M Perry; S Zhang; A Tzankov; H Rao; J Abramson; A R Sohani; M Xu; E D Hsi; J Zhu; M Ponzoni; S Wang; Ling Li; M Zhang; A J M Ferreri; B M Parsons; Y Li; M A Piris; L J Medeiros; K H Young Journal: Leukemia Date: 2013-08-26 Impact factor: 11.528
Authors: Arati A Inamdar; Andre Goy; Nehad M Ayoub; Christen Attia; Lucia Oton; Varun Taruvai; Mark Costales; Yu-Ting Lin; Andrew Pecora; K Stephen Suh Journal: Oncotarget Date: 2016-07-26